prof. MUDr. Marta Krejčí, Ph.D.
Professor, Department of Internal Medicine - Hematology and Oncology
correspondence Address:
Jihlavská 340/20, 625 00 Brno
| phone: | +420 532 23 2215, 3603 |
|---|---|
| e‑mail: |
| social and academic networks: |
|---|
Total number of publications: 449
2026
-
Autologous stem cell transplantation as bridging therapy prior to idecabtagene vicleucel (ide-cel) in multiple myeloma: a single-centre experience
Year: 2026, type: Conference abstract, DOI
-
CD38 expression in paraskeletal and extramedullary plasmacytomas in multiple myeloma: assessment in relation to anti-CD38 therapy
Year: 2026, type: Conference abstract, DOI
-
High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas
HemaSphere, year: 2026, volume: 10, edition: 6, DOI
-
Tumor-specific cell-free DNA for monitoring disease activity in multiple myeloma with paraskeletal and extramedullary plasmacytomas
Year: 2026, type: Conference abstract, DOI
2025
-
Hodnocení minimální zbytkové choroby u extraoseálního mnohočetného myelomu
Year: 2025, type: Conference abstract
-
Léčba unicentrické Castlemanovy choroby rituximabem, bendamustinem a dexametazonem zmenšila objem neoperabilního expanzivního ložiska v horním mediastinu a umožnila jeho radikální odstranění
Klinická onkologie, year: 2025, volume: 38, edition: 2, DOI
-
Precizní medicína v hematoonkologii - léčba refrakterního mnohočetného myelomu s masivním extramedulárním postižením BRAF/MEK inhibitory
Klinická onkologie, year: 2025, volume: 38, edition: 5, DOI
2024
-
CIRCULATING TUMOR CELLS HAVE HIGH PROGNOSTIC SIGNIFICANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH PARASKELETAL OR EXTRAMEDULLARY PLASMACYTOMAS
Year: 2024, type: Conference abstract
-
Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease
Blood Cancer Journal, year: 2024, volume: 14, edition: 1, DOI
-
EFFICACY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE REGIMEN IN DARATUMUMAB-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE ANALYSIS
Year: 2024, type: Conference abstract